1-[2-[4-[(1R,2S)-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenoxy]ethyl]pyrrolidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[2-[4-[(1R,2S)-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenoxy]ethyl]pyrrolidine
• 化学式: C₂₈H₃₁NO
• 分子量: 397.6
• InChiKey: VWONEXHDGRTGJF-VSGBNLITSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Growth hormone secretagogues
  申请人：Pfizer Products Inc.

  公开号：EP0995748B1

  公开（公告）日：2004-03-31
• USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES FOR TREATING INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES
  申请人：NOVO NORDISK A/S

  公开号：EP1143979A1

  公开（公告）日：2001-10-17
• [EN] USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES FOR TREATING INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES<br/>[FR] UTILISATION D'OESTROGENES ET DE DELTA-GONADIENE-21-OL-3,20-DIONES DANS LE TRAITEMENT DES DIABETES INSULINO-DEPENDANT ET NON INSULINO-DEPENDANT
  申请人：NOVO NORDISK AS

  公开号：WO2000041701A1

  公开（公告）日：2000-07-20

  The present invention relates to the use of a combination of estrogens or SERMs with delta-gonadien-21-ol-3,20-diones for treating diabetes, particularly type II diabetes. It also embraces pharmaceutical compositions and kits comprising these compounds and methods of using the compounds and their pharmaceutical compositions.
• [EN] USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES IN THE TREATMENT OR PROPHYLAXIS OF CEREBRAL DEGENERATIVE DISORDERS<br/>[FR] UTILISATION D'OESTROGENES ET DE DELTA-GONADIENE-21-OL-3,20-DIONES DANS LE TRAITEMENT OU LA PREVENTION DE MALADIES DEGENERATIVES DU CERVEAU
  申请人：NOVO NORDISK AS

  公开号：WO2000041700A1

  公开（公告）日：2000-07-20

  The present invention relates to the use of a combination of estrogens or SERMs with delta-gonadien-21-ol-3,20-diones for the treatment of patients suffering from cerebral degenerative disorders, e.g. Alzheimer's disease, and prophylaxis hereof.